Multiple Lung Metastasectomy for the Poor Differentiated Metastatic Synovial Sarcoma

Česká verzia

Authors: V. Jedlička; J. Doležel; P. Vlček; A. Peštál; K. Veselý ^*; O. Bednařík ^**; I. Čapov
Authors place of work: I. chirurgická klinika FN u sv. Anny a LF MU v Brně, přednosta: prof. MUDr. I. Čapov, CSc. ; I. patologicko-anatomický ústav FN u sv. Anny a LF MU Brno, přednosta: prof. MUDr. A. Rejthar, CSc. ^*; Oddělení klinické a radiační onkologie FN u sv. Anny v Brně, přednosta prim. MUDr. V. Spurný, CSc. ^**
Published in the journal: Rozhl. Chir., 2007, roč. 86, č. 2, s. 85-88.
Category: Monothematic special - Original

Summary

Objectives:
Synovial sarcoma is the rare indication for the pulmonary metastasectomy due to its aggressive biologic behavior and early dissemination. The radical surgical approach in therapy of the multiple pulmonary metastases could improve quality of life and median survival in carefully selected patients.

Methods:
From the group of 7 patients with the lung metastases of the synovial sarcoma operated in our department during the last 5 years we are presenting the case of the 39 years old man with the previous history of the surgical removal of the synovial sarcoma near the cubital fossa one year before. Considering the lungs as the only organ involved, bilateral complete metastasectomy through muscle sparing vertical thoracotomies was done. There were 12 metastases from all lung lobes with the exception of the right middle lobe. Analysis of the pathologist showed biphasic metastatic synovial sarcoma with the high mitotic activity. The 6 cycles of the MAID regime succeeded.

Results:
Median survival of the whole group is 25 months, there are 3 patients alive. In the above mentioned patient 1 year after the metastasectomy PET-CT showed focus of the 4th left rib suspected to be malignant. Wide resection of the rib was done, but no malignancy was disclosed, there were only reparative changes. The patient has been tolerated the oncological treatment very well and 45 months after the lung metastasectomy there are no sings of a malignant disease.

Conclusion:
Lung metastasectomy of the multiple lung metastases of the synovial sarcoma is of value despite of uncertain long-term prognosis. It is recommended to consider the metastasectomy even in low differentiated tumors. The prerequisite for the effective treatment is a complete resection.

Key words:
multiple lung metastases – bilateral lung metastastasectomy – synovial sarcoma

Zdroje

1. Pastorino, U., Grunenwald, D. Pulmonary metastases. In: Pearson, F., G., ed.: Thoracic Surgery. 2nd ed., Churchill Livingstone, 2002, Philadelphia, USA, 962–973.

2. Žaloudík, J., Talač, R., Vagunda, V., et al. Sarkomy měkkých tkání – přehled novějších diagnostických a léčebných postupů. Klin. Onkol., 2000, 13, 143–150.

3. Spillane, A. J., A‘Hern, R., Judson, R. I., Fisher, C., Meirion Thomas, J. Synovial sarcoma: A Clinicopathologic, Staging, and Prognostic Assessment. J. Clin. Oncol., 2000, 18, 3794–3803.

4. Pastorino, U., Buyse, M., Friedel, G., et al. for the International Registry of Lung Metastases: Long-term results of lung metastasectomy: prognostic analyses based on 5,206 cases. J. Thorac. Cardiovasc. Surg., 1997, 113, 1, 37–49.

5. Billingsley, K. G., Burt, M. E., Jara, E., Ginsberg, R. J., Woodruff, J. M., Leung, D. H. Y., Brennan, M. F. Pulmonary metastases from soft tissue sarcoma. Analysis of Patterns of Disease and Postmetastasis Survival. Annals of Surgery, 1999, 229, 5, 602–612.

6. Spurrell, E. L., Fischer, C., Thomas, J. M, Judson, I. R. Prognostic factors in advanced synovial sarcoma: an analysis oof 104 patients treated at the Royal Marsden Hospital. Annals of Oncology, 2005, 16, 437–444.

7. Belal, A., Salah, E., Hajjar, W., El-Foudeh, M., Memon, M., Ezzat, A., Al-Kattan, K. Pulmonary metastasectomy for soft tissue sarcomas: is it valuable? J. Cardiovasc. Surg., 2001, 42, 835–840.

8. Asamura, H., Nakayama, H., Kondo, H., et al. Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J. Thorac. Cardiovasc. Surg., 1999, 117, 6, 1102–1111.

9. Burt, M. E., Liu, D., Abolhoda, A., Ross, H. M., Ross, H. M., Kaneda, Y., Jara, E., Casper, E. S., Ginsberg, R. J., Brennan, M. F. Isolated lung perfusion for patients with unresectable metastases from sarcoma: A Phase I trial. Ann. Thorac. Surg., 2000, 69, 1542–1549.

10. Hendriks, J. M., Grootenboers, M. J., Schramel, F. M., van Boven, W. J., Stockman, B., Seldenrijk, C. A., ten Broecke, P., Knibbe, C. A., Slee, P., De Bruijn, E., Vlaeminck, R., Heeren, J., Vermorken, J. B., van Putte, B., Romijn, S., Van Marck, E., Van Schil, P. E. Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial. Ann. Thorac. Surg., 2004, 78, 6, 1919–1926.